Previous 10 | Next 10 |
IDEAYA Biosciences (IDYA) has submitted an Investigational New Drug ((IND)) application with the FDA for the initiation of a Phase 1 clinical trial to evaluate IDE397 for the treatment of patients having solid tumors with methylthioadenosine phosphorylase ((MTAP)) deletion.IDEAYA Bioscie...
IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors IDE397 pr...
IDEAYA Biosciences (IDYA) announces First-Patient-In ((FPI)) in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma ((MUM)).The combination is being evaluated by IDEAYA in collaboration with Pfizer (PFE) pursuant to a supply agreement. Precli...
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medi...
IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences PR Newswire SOUTH SAN FRANCISCO , Calif., Jan. 4, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company c...
IDEAYA Biosciences ([[IDYA]] -1.5%), I-Mab ([[IMAB]] +2.4%) & Immunic ([[IMUX]] +3.9%) were selected for addition to the NASDAQ Biotechnology Index, effective Dec.21, 2020 before market opens."Since its IPO on Nasdaq in January 2020, I-Mab has successfully executed many imp...
IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index SOUTH SAN FRANCISCO, Calif. , Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targ...
IDEAYA Biosciences is an oncology specialist focused on precision medicine aiming to utilize molecular diagnostics to develop targeted therapeutics with a research focus on synthetic lethality. The company has two clinical phase therapeutics and six others in the pre-clinical/IND phas...
IDEAYA Biosciences (IDYA): Q3 GAAP EPS of -$0.17.Revenue of $8.99MPress Release For further details see: IDEAYA Biosciences reports Q3 results
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update - IDE397, a potential best-in-class MAT2A inhibitor for patients with solid tumors having MTAP deletion, targeting an IND-filing in December 2020 - PARG and Pol Theta programs ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...